Anaplastic lymphoma kinase inhibitors: an updated patent review (2014–2018)

References

• Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta. 2009;1795(1):37–52.
   PubMed Web of Science ®Google Scholar
• Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117–1134.
   PubMed Web of Science ®Google Scholar
• Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor kinase expressed specifically in the nervous system. Oncogene. 1997;14(4):439–449.
   PubMed Web of Science ®Google Scholar
• Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in Non-Hodgkin’s lymphoma. Science. 1994;263(5151):1281–1284.
   PubMed Web of Science ®Google Scholar
• Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Can Res. 2015;21(10):2227–2235.
   PubMed Web of Science ®Google Scholar
• Motegi A, Fujimoto J, Kotani M, et al. ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J Cell Sci. 2004;117(15):3319–3329.
   PubMed Web of Science ®Google Scholar
• Stoica GE, Kuo A, Aigner A, et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Bio Chem. 2001;276(20):16772–16779.
   PubMed Web of Science ®Google Scholar
• Stoica GE, Kuo A, Powers C, et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Bio Chem. 2002;277(39):35990–35998.
   PubMed Web of Science ®Google Scholar
• Mathivet T, Mazot P, Vigny M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? Cell Signal. 2007;19(12):2434–2443.
   PubMed Web of Science ®Google Scholar
• Moog-Lutz C, Degoutin J, Gouzi JY, et al. Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of Pleiotrophin. J Bio Chem. 2005;280(28):26039–26048.
   PubMed Web of Science ®Google Scholar
• Murray PB, Lax I, Reshetnyak A, et al. Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK. Sci Signal. 2015;8(360):ra6.
   PubMed Web of Science ®Google Scholar
• Guan J, Umapathy G, Yamazaki Y, et al. FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase. ELife. 2015;4:e09811.
   PubMed Web of Science ®Google Scholar
• Reshetnyak AV, Murray PB, Shi X, et al. Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: hierarchy and specificity of ligand-receptor interactions. Proc Natl Acad Sci U S A. 2015;112(52):15862–15867.
   PubMed Web of Science ®Google Scholar
• Holla VR, Elamin YY, Bailey AM, et al. ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harb Case Stud. 2017;3(1):a001115.
   PubMed Web of Science ®Google Scholar
• Lee CC, Jia Y, Li N, et al. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J. 2010;430(3):425–437.
   PubMedGoogle Scholar
• Wu W, Haderk F, Bivona TG. Non-canonical thinking for targeting ALK-fusion onco-proteins in lung cancer. Cancers (Basel). 2017;9(12):E164.
   PubMed Web of Science ®Google Scholar
• Aubry A, Galiacy S, Allouche M. Targeting ALK in cancer: therapeutic potential of proapoptotic peptides. Cancers (Basel). 2019;11(3):E275.
   PubMed Web of Science ®Google Scholar
• Sharma GG, Mota I, Mologni L, et al. Tumor resistance against ALK targeted therapy-where it comes from and where it goes. Cancers (Basel). 2018;10(3):E62.
   PubMed Web of Science ®Google Scholar
• Della Corte CM, Viscardi G, Di Liello R, et al. Role and targeting of anaplastic lymphoma kinase in cancer. Mol Cancer. 2018;17(1):30.
   PubMedGoogle Scholar
• Cao Z, Gao Q, Fu M, et al. Anaplastic lymphoma kinase fusions: roles in cancer and therapeutic perspectives. Oncol Lett. 2019;17(2):2020–2030.
   PubMed Web of Science ®Google Scholar
• Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in Non-Hodgkin’s lymphoma. Science. 1995;267(5196):316–317.
   PubMed Web of Science ®Google Scholar
• Lamant L, Dastugue N, Pulford K, et al. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood. 1999;93(9):3088–3095.
   PubMed Web of Science ®Google Scholar
• Liang X, Meech SJ, Odom LF, et al. Assessment of t(2;5)(p23;q35) translocation and variants in pediatric ALK+ anaplastic large cell lymphoma. Am J Clin Pathol. 2004;121(4):496–506.
   PubMed Web of Science ®Google Scholar
• Colleoni GW, Bridge JA, Garicochea B, et al. ATIC-ALK: a novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am J Pathol. 2000;156(3):781–789.
   PubMed Web of Science ®Google Scholar
• Lawrence B, Perez-Atayde A, Hibbard MK, et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol. 2000;157(2):377–384.
   PubMed Web of Science ®Google Scholar
• Bridge JA, Kanamori M, Ma Z, et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol. 2001;159(2):411–415.
   PubMed Web of Science ®Google Scholar
• Ma Z, Hill DA, Collins MH, et al. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer. 2003;37:98–105.
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566.
   PubMed Web of Science ®Google Scholar
• Golding B, Luu A, Jones R, et al. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer. 2018;17(1):52.
   PubMedGoogle Scholar
• Spagnuolo A, Maione P, Gridelli C. Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors. Expert Opin Emerg Drugs. 2018;23(3):231–241.
   PubMed Web of Science ®Google Scholar
• Kelly LM, Barila G, Liu P, et al. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A. 2014;111(11):4233–4238.
   PubMed Web of Science ®Google Scholar
• Ji JH, Oh YL, Hong M, et al. Identification of driving ALK fusion genes and genomic landscape of medullary thyroid cancer. PLoS Genet. 2015;11(8):e1005467.
   PubMed Web of Science ®Google Scholar
• Katayama R. Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer. Cancer Sci. 2018;109(3):572–580.
   PubMed Web of Science ®Google Scholar
• Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363(18):1734–1739.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013;19(15):4273–4281.
   PubMed Web of Science ®Google Scholar
• Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662–673.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6(10):1118–1133.
   PubMed Web of Science ®Google Scholar
• Katayama R, Friboulet L, Koike S, et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res. 2014;20(22):5686–5696.
   PubMed Web of Science ®Google Scholar
• Pacenta HL, Macy ME. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma. Drug Des Devel Ther. 2018;12:3549–3561.
   PubMed Web of Science ®Google Scholar
• Malik SM, Maher VE, Bijwaard KE, et al. U.S. food and drug administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res. 2014;20(8):2029–2034.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31(8):1105–1111.
   PubMed Web of Science ®Google Scholar
• Steuer CE, Ramalingam SS. ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options. Cancer. 2014;120(16):2392–2402.
   PubMed Web of Science ®Google Scholar
• Rothenstein JM, Chooback N. ALK inhibitors, resistance development, clinical trials. Curr Oncol. 2018;25(Suppl 1):S59–S67.
   PubMedGoogle Scholar
• Li S, Qi X, Huang Y, et al. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer. Clin Lung Cancer. 2015;16(2):86–91.
   PubMed Web of Science ®Google Scholar
• Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917–929.
   PubMed Web of Science ®Google Scholar
• Vavalá T, Novello S. Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy. Ther Adv Med Oncol. 2018;10:1758835918789364.
   Web of Science ®Google Scholar
• Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014;74(5):1023–1028.
   PubMed Web of Science ®Google Scholar
• Novello S, Maziéres J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinibpretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29(6):1409–1416.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol. 2019;pii:S1556-0864(19)30210–2.
   Google Scholar
• Gadgeel S, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018;29(11):2214–2222.
   PubMed Web of Science ®Google Scholar
• Markham A. Brigatinib: first global approval. Drugs. 2017;77(10):1131–1135.
   PubMed Web of Science ®Google Scholar
• Gettinger SN, Bazhenoval LA, Langer CJ, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(12):1683–1696.
   PubMed Web of Science ®Google Scholar
• Passaro A, Prelaj A, Pochesci A, et al. Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients. Drugs Today (Barc). 2017;53(8):435–446.
   PubMed Web of Science ®Google Scholar
• Drilon A, Siena S, Ou SI, et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7:400–409.
   PubMed Web of Science ®Google Scholar
• Waqar SN, Morgensztern D. Lorlatinib: a new-generation drug for ALK-positive NSCLC. Lancet Oncol. 2018;19(12):1555–1557.
   PubMed Web of Science ®Google Scholar
• Colloer TL, Maresca KP, Normandin MD, et al. Brain penetration of the ROS1/ALK inhibitor lorlatinib confirmed by PET. Mol Imaging. 2017;16:1536012117736669.
   Web of Science ®Google Scholar
• Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18(12):1590–1599.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654–1667.
   PubMed Web of Science ®Google Scholar
• Syed YY. Lorlatinib: first global approval. Drugs. 2019;79(1):93–98.
   PubMed Web of Science ®Google Scholar
• Horn L, Infante JR, Reckamp KL, et al. Ensartinib (X-396) in ALK-positive non- small cell lung cancer: results from a first-in-human phase I/II, multicenter study. Clin Cancer Res. 2018;24(12)2771–2779.
   PubMed Web of Science ®Google Scholar
• Arkenau HT, Sachdev JC, Mita MM, et al. Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer. J Clin Onco. 2015;33(15_suppl):abstract 8063.
   Web of Science ®Google Scholar
• Drilon A, Ou SI, Cho BC, et al. Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations. Cancer Discov. 2018;8(10):1227–1236.
   PubMed Web of Science ®Google Scholar
• Ott GR, Cheng M, Learn KS, et al. Discovery of clinical candidate CEP-37440, a selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK). J Med Chem. 2016;59(16):7478–7496.
   PubMed Web of Science ®Google Scholar
• Cheng M, Quail MR, Gingrich DE, et al. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2012;11(3):670–679.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang L, Guan S, et al. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis. Sci Rep. 2016;6(1):19423.
   PubMedGoogle Scholar
• Zhejiang Daoming Pharmaceutical Technology CO., LTD, Three-level cyclic amine ALK kinase inhibitor for treating cancer. WO2014146486A1. 2014.
   Google Scholar
• Wuhan Optical Vally Humanwell Biological Pharmaceutical CO., LTD, Compound and preparation method therefor and uses thereof. WO2015158025A1. 2015.
   Google Scholar
• Novartis, Compounds and compositions as protein kinase inhibitors. US8957081B2. 2015.
   Google Scholar
• Beijing Pearl Biotechnology Limited Liability Company, ALK kinase inhibitor, and preparation method and use thereof. EP3150592A1. 2015.
   Google Scholar
• Korea Research Institute of Chemical Technology, Pyrimidine-2,4,-diamine derivative and pharmaceutical anticancer composition containing same as active ingredient. WO2015130014A1. 2015. .
   Google Scholar
• KBP Biosciences CO., LTD, Tetracyclic anaplastic lymphoma kinase inhibitor. CN105524045A. 2016.
   Google Scholar
• KBP Biosciences CO., LTD, Tricyclic and fused-cyclic ALK (anaplastic lymphoma kinase) inhibitors. CN106146525A. 2016.
   Google Scholar
• Hubei Biological Medicine Industrial Technology Institute CO., LTD. and Humanwell Healthcare (Group) CO., LTD, Kinase inhibitor and application thereof. WO2016192131A1. 2016.
   Google Scholar
• Hubei Biological Medicine Industrial Technology Institute CO., LTD. and Humanwell Healthcare (Group) CO., LTD, Pyrimidine derivative and use thereof. WO2017076355A1. 2017.
   Google Scholar
• Korea Research Institute of Chemical Technology, Pharmaceutical composition inducing decomposition of ALK protein, and pharmaceutical composition for cancer prevention or treatment containing same as active component. WO2017204445A2. 2017. .
   Google Scholar
• Kang CH, Lee DH, Lee CO, et al. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC). Biochem Biophys Res Commun. 2018;505(2):542–547.
   PubMed Web of Science ®Google Scholar
• KBP Biosciences CO., LTD, Tetra-heterocyclic-fused anaplastic lymphoma kinase inhibitor. CN104804016A. 2015.
   Google Scholar
• Chugai Seiyaku Kabushiki Kaisha, Tetracyclic compound. US9440922B2. 2016.
   Google Scholar
• Jiangsu ascentage biomed development INC, Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors. WO2015127629A1. 2015.
   Google Scholar
• Dana-Farber cancer institute, INC, Inhibitors of ALK and SPRK and methods of use. WO2017053657A1. 2017.
   Google Scholar
• Hai Peng Chen, A kind of tricyclic compounds containing cyano and its purpose in antitumor drug. CN108467397A. 2018.
   Google Scholar
• Hai Peng Chen, Compound, synthesizing method and application thereof in preparing antitumor drugs. CN108484615A. 2018.
   Google Scholar
• Hai Peng Chen, Tricyclic compound containing cyano group and application thereof in preparing antineoplastic drugs. CN108558886A. 2018.
   Google Scholar
• Beijing Kyning Bioscience Co. Ltd, Deuterated crizotinib and derivative thereof, preparation method and application. CN104327053A. 2015. .
   Google Scholar
• Shen-Zhen targetrx, INC, Macrocycle and composition comprising thereof. WO2017148325A1. 2017. .
   Google Scholar
• Chia Tai Tianqing pharmaceutical group CO., LTD, Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof. WO2017088784A1. 2017. .
   Google Scholar
• Shanghai Fochon pharmaceutical CO., LTD. and Shanghai Institute of Material Medica Chinese Academy of Sciences, Certain protein kinase inhibitors. US20160046638A1. 2016.
   Google Scholar
• Cephalon, Inc, Pyrrolotriazines as ALK inhibitors. US20160347756A1. 2016.
   Google Scholar
• Wisdom Pharmaceutical Co., Ltd, Alk class of kinase inhibitors and a method for preparing. CN105085550B. 2017.
   Google Scholar
• ZheJiang University, Pyrazolo[3,4-b]pyridine compound, preparation method and application thereof. CN108774224A. 2018.
   Google Scholar
• China Pharmaceutical University, Antitumor application of tricyclic compounds. CN104473921A. 2015.
   Google Scholar
• Macau University of Science and Technology, Oncogenic ROS1 and ALK kinase inhibitor. US9782400B2. 2017. .
   Google Scholar
• Yancheng Fengrui Biotechnology, ALK/c-MET double inhibitor and its application. CN108033965A. 2018.
   Google Scholar
• Cephalon, Inc, Macrocyclic compounds as ALK, FAK and JAK2 inhibitors. US20170027948A1. 2017. .
   Google Scholar
• TP Therapeutics, Inc, Diaryl macrocycles as modulators of protein kinases. WO2015112806A2. 2015.
   Google Scholar
• Camidge DR, Otterson GA, Clark JW, et al. Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): updated safety and efficacy findings from a phase 1 trial. J Clin Oncol. 2018;36(15_suppl):9062.
   Google Scholar
• Engelhardt H, Bose D, Petronczki M, et al. Start selective and rigidify: the discovery path toward a next generation of EGFR tyrosine kinase inhibitors. J Med Chem. 2019;62(22):10272–10293.
   PubMed Web of Science ®Google Scholar
• Testa A, Hughes SJ, Lucas X, et al. Structure-based design of a macrocyclic PROTAC. Angew Chem Int Ed Engl. 2019;58:2–10.
   Google Scholar
• Balazs AYS, Carbajo RJ, Davies NL, et al. Free ligand 1D NMR conformational signatures to enhance structure based drug design of a Mcl-inhibitor (AZD5991) and other synthetic macrocycles. J Med Chem. 2019;62(21):9418–9437.
   PubMed Web of Science ®Google Scholar